Ionis Pharmaceuticals: Compelling Long-Term Commercial UpsideSeeking Alpha · 9 hr ago
Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)Business Wire · 2 days ago
Ionis ranked #1 on Science's Top Employers listGuruFocus · 3 days ago
Ionis ranked #1 on Science's Top Employers listBusiness Wire · 3 days ago
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)GuruFocus · 5 days ago
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)Business Wire · 5 days agoFounded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 29, 2026 | -$1.09 | -$0.69 | Beat |
| Apr 29, 2026 | -$0.85 | -$0.56 | Beat |
| Feb 25, 2026 | -$1.24 | -$1.41 | Miss |
| Oct 29, 2025 | -$1.15 | -$0.61 | Beat |
| Jul 30, 2025 | $0.27 | $0.86 | Beat |
| Apr 30, 2025 | -$1.11 | -$0.75 | Beat |